Trial Information
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies
Inclusion Criteria:
- Histological or cytological confirmation of a solid, malignant tumour
Exclusion Criteria:
- Participation in an investigational drug study within 21 days prior to entry or who
have not recovered from the effects of an investigational study drug
- Treatment with radiotherapy/chemotherapy with 4 weeks of first dose
- Recent major surgery within 4 weeks prior to entry to the study
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety and Tolerability
Outcome Time Frame:
Assessed at each visit
Principal Investigator
David Kerr, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Oxford
Authority:
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study ID:
D1531C00003
NCT ID:
NCT00497679
Start Date:
August 2006
Completion Date:
July 2007
Related Keywords:
- Solid Tumours
- advanced solid tumours
